Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
56,260,480
-
Number of holders
-
35
-
Total 13F shares, excl. options
-
5,230,260
-
Shares change
-
+946,051
-
Total reported value, excl. options
-
$6,956,589
-
Value change
-
+$1,241,119
-
Put/Call ratio
-
37%
-
Number of buys
-
16
-
Number of sells
-
13
-
Price
-
$1.33
Institutional Holders of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) as of Q1 2025
44 filings reported holding QNCX - Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share as of 31 Mar 2025.
Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) had 35 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 5,230,260 shares of stock of the company.
Largest 10 holders included VANGUARD GROUP INC, IEQ CAPITAL, LLC, RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock, Inc., HighTower Advisors, LLC, Alphabet Inc., TANG CAPITAL MANAGEMENT LLC, Shay Capital LLC, and ADAR1 Capital Management, LLC.
This table shows the top 35 institutional shareholders of the security as of 31 Mar 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.